{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Cytoskeleton > LifitegrastCAS：1025967-78-5
Molecular Formula：C29H24Cl2N2O7S
Molecular Weight：615.48
Storage：Powder:-20℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥98%
Appearance：White to off-white Solid
Qty：
Size：
| CAS | 1025967-78-5 |
| Name | Lifitegrast |
| Molecular Formula | C29H24Cl2N2O7S |
| Molecular Weight | 615.48 |
| Solubility | Soluble in DMSO |
| Purity | ≥98% |
| Appearance | White to off-white Solid |
| Storage | Powder:-20℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| EC | EINECS 813-044-8 |
| MDL | MFCD28502439 |
| SMILES | O=C(O)[C@H](CC1=CC=CC(S(=O)(C)=O)=C1)NC(C2=C(Cl)C3=C(CN(C(C4=CC=C5C=COC5=C4)=O)CC3)C=C2Cl)=O |
| Target Point | Integrin |
| Passage | Cytoskeleton |
| Background | Lifitegrast is a novel integrin antagonist. |
| Biological Activity | Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1)， interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease[1]. |
| In Vitro | Lifitegrast(SAR 1118)inhibits T cell-mediated inflammation by blocking the binding of two important cell surface proteins(lymphocyte function-associated antigen 1 and intercellular adhesion molecule 1)，thus lessening overall inflammatory responses[1]. |
| In Vivo | Lifitegrast(SAR 1118)，has potent anti-inflammatory activity on corneal inflammation induced by antibiotic-killed P. aeruginosa and S. aureus in the presence of a silicone hydrogel lens with the optimal application being a 1% solution applied either 2 or 3 times prior[2]. |
| Animal Experiment | Mice: The role of LFA-1(CD11a/CD18)is examined either in CD18-/- mice，by intraperitoneal injection of anti-CD11a，or by topical application of lifitegrast. Corneal inflammation is induced by epithelial abrasion and exposure to either tobramycin-killed Pseudomonas aeruginosa or Staphylococcus aureus in the presence of a 2-mm-diameter punch from a silicone hydrogel contact lens. After 24 h，corneal thickness and haze are examined by confocal microscopy，and neutrophil recruitment to the corneal stroma is detected by immunohistochemistry[2]. |
| Data Literature Source | [1]. Perez VL，et al. Lifitegrast，a Novel Integrin Antagonist for Treatment of Dry Eye Disease. Ocul Surf. 2016 Apr;14(2):207-15. [2]. Sun Y，et al. Corneal inflammation is inhibited by the LFA-1 antagonist，lifitegrast (SAR 1118). J Ocul Pharmacol Ther. 2013 May;29(4):395-402. |
| Unit | Bottle |
| Specification | 2mg 5mg |
Lifitegrast是一种新型的integrin拮抗剂。
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
